Parkinson Disease
Conditions
Brief summary
Parkinson's disease is defined as the progressive loss or deterioration of dopaminergic neurons, Treatment approaches to maintain the normal dopamine level that include medication, surgery, cell therapy supplementation of L-Dihydroxyphenylalanine (L-Dopa), a precursor of dopamina, Stem cells from bone marrow can be mobilized according to the need of repair of the tissue. Suggested use of the food supplement actually sold in the USA and in Europe: Take two capsules, 1 to 3 times per day with a glass of water. Increase the Stem Cell circulating in the peripheral blood.
Detailed description
Parkinson's disease is defined as the progressive loss or deterioration of dopaminergic neurons in Substantia Nigra (SN) of the brain. These cells normally produce dopamine which acts like a messenger for normal muscular movement. Having less quantity of dopamine in the synaptic cleft due to the loss of neural cells, symptoms become apparent. Neuroinflammation and oxidative stress are involved. Treatment approaches to maintain the normal dopamine level that include medication, surgery, cell therapy supplementation of L-Dihydroxyphenylalanine (L-Dopa), a precursor of dopamine, in the form of Levodopa and/or Carbidopa, has been available for PD therapy for 50 years. Stem cells constitute the repair system of the body. Stem cells from bone marrow can be mobilized according to the need of repair of the tissue. Suggested use of the food supplement actually sold in the USA and Europe: Take two capsules, 1 to 3 times per day with a glass of water. All raw materials are food grade. All extracts are water or ethanolic extracts, which are authorized solvents for dietary supplements in the USA and EU. All ingredients are compliant with US and EU contaminants regulation (microbiological profile, heavy metals, pesticides) especially EU pharmacopeia, the product shows to increase Stem Cell circulation in peripheral blood.
Interventions
DIETARY_SUPPLEMENTStemRegen product
Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible: Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance.
Sponsors
Sociedad Española de Medicina Regenerativa y Terapia Celular
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group Assignment
Eligibility
Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Adults from both genders * Diagnosed by neurologist or qualified health care practitioner with PD for 5 years or more * Stabilized symptomatic treatment for PD for more than 3 months * Age: over 21 years old * Volunteers able to understand the nature of the study and to sign a written consent form
Exclusion criteria
* Gastro-intestinal surgery that may modify or decrease the intestinal absorption of nutrient and experimental product * Serious traumatism in the last 3 months * Heavy surgery operation in the last 3 months * Non-controlled evolutive disease * Drug or medication abuse in the last 2 years * History of non-compliance in previous studies * Regular consumption of similar ingredients or food supplements compared to experimental product in the past 3 months * Any medical problem or trouble identified by the investigator that could alter the capacity of the volunteer to end the study * Any drug medication that could mask, decrease or interfere experimental product efficacy * Surgery operation planned during the year * Breastfeeding, pregnant women * Known allergies to one of the ingredients entering in the composition of the experimental product * Severe liver and renal failure * Actual participation to another clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 6 months | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Parkinson's Disease (PD) symptoms: Change from Baseline | 6 months | UPDRS questionnaire which represents a validated and standardized questionnaire for PD diagnostic and disease progression evaluation: 0=normal - 4= Severe |
| Quality of Life Assessed by the Parkinson's Disease | 6 Months | Modified SF-36 quality of life assessment from Dr Gitte Jensen used in several clinical studies at NIS labs clinical center, Oregon USA, result from excellent to Terrible |
| Parkinson's Disease (PD) symptoms: Change | 6 months | Schwab and England activities of daily living activities scales from 0% to 100% |
Countries
Spain
Contacts
Primary ContactMiguel G Garber, MD
Backup ContactFelix Pedrero, MD
Outcome results
None listed